SLC5A2 and diabetic kidney disease: These various therapeutic mechanisms of SGLT2 inhibitors would be beneficial to slow the progression of DKD as several pathophysiological disorders contribute to the progression of the disease; therefore, combination of multiple drugs has been prescribed in clinic so far (DeFronzo et al., 2021).